Discovery of XNW5004 as a novel EZH2 inhibitor that enhances anti-tumor immunity and synergizes with PD-1 blockade immunotherapy in lung adenocarcinoma.
A new cancer drug makes immunotherapy more effective by boosting immune cell activity, showing promise in lung cancer.
XNW5004, a novel EZH2 inhibitor, enhances immune-mediated tumor killing and synergizes with anti-PD-1 in lung adenocarcinoma via STING-TBK1-NF-kB-mediated MHC-I upregulation and DC/T cell recruitment. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- preclinical in vitro and in vivo study (cell lines + C57BL/6 mice)
- Category
- novel_therapeutics
- Maturity
- Exploratory
- Journal
- J Transl Med
Why it surfaced
Novel EZH2 inhibitor (XNW5004) with mechanistic evidence for immune synergy via STING-TBK1-NF-kB/MHC-I axis in lung adenocarcinoma, providing rationale for EZH2+PD-1 combination clinical trials.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.